SNPs in the APM1 gene promoter are associated with adiponectin levels in HIV-infected individuals receiving HAART.
OBJECTIVE
This study aimed to investigate the association between 4 polymorphisms in the leptin, leptin receptor, and adiponectin (APM1) genes and the occurrence of lipodystrophy and dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy (HAART).


METHODS
Genotypes of 410 HIV-infected patients on HAART were investigated. Anthropometric (weight, height, waist circumference and skinfolds thickness) and biochemical (blood lipids, glucose, leptin, and adiponectin levels) parameters were evaluated. Genotype frequencies were compared between patients with or without lipodystrophy. Mean biochemical and anthropometric parameters were compared between the different genotypes.


RESULTS
Lipodystrophy prevalence was 53.4%. Genotype frequencies were not different between patients with or without lipodystrophy. Carriers of the A allele for the APM1-11391 G.A and of the C allele for APM1-11377 C.G presented higher adiponectin levels compared to other genotypes, and carriers of the -11391A-11377C haplotype when compared with carriers of other haplotypes.


CONCLUSIONS
SNPs in APM1 gene are associated with adiponectin levels in HIV-infected patients receiving HAART and may thus affect the occurrence of metabolic alterations in these patients. No influence of the leptin and leptin receptor gene polymorphisms on the occurrence of lipodystrophy and dyslipidemia was observed.
Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.
Juciane R
JR
Trinca
Eduardo
E
Sprinz
Rosmeri K
RK
Lazzaretti
Mara H
MH
Hutz
Regina
R
Kuhmmer
Silvana
S
de Almeida
Analise
A
Tibola
Gustavo B
GB
Meirelles
Roberto C
RC
Arena-de-Souza
Vanessa S
VS
Mattevi
D052242:Adiponectin / Q000097:blood / Q000235:genetics; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000235:genetics*; D006801:Humans; D020738:Leptin / Q000235:genetics; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D054411:Receptors, Leptin / Q000235:genetics
C499918:ADIPOQ protein, human; D052242:Adiponectin; D019380:Anti-HIV Agents; C515448:LEPR protein, human; D020738:Leptin; D054411:Receptors, Leptin